Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Vaccination Against Rabbit Hemorrhagic Disease Virus 2 Using a Baculovirus Recombinant Vaccine Provides Durable Immunity in Rabbits

Version 1 : Received: 19 February 2024 / Approved: 20 February 2024 / Online: 20 February 2024 (07:11:11 CET)

A peer-reviewed article of this Preprint also exists.

Bosco-Lauth, A.M.; Schueler, A.; Midthun, E.; Tyra, H.; Held, A.; Hood, C.; Quilici, M.; Erickson, S.; Glover, S.; Gustafson, B.; Anderson, G. Vaccination against Rabbit Hemorrhagic Disease Virus 2 (RHDV2) Using a Baculovirus Recombinant Vaccine Provides Durable Immunity in Rabbits. Viruses 2024, 16, 538. Bosco-Lauth, A.M.; Schueler, A.; Midthun, E.; Tyra, H.; Held, A.; Hood, C.; Quilici, M.; Erickson, S.; Glover, S.; Gustafson, B.; Anderson, G. Vaccination against Rabbit Hemorrhagic Disease Virus 2 (RHDV2) Using a Baculovirus Recombinant Vaccine Provides Durable Immunity in Rabbits. Viruses 2024, 16, 538.

Abstract

Rabbit hemorrhagic disease virus disease 2 (RHDV2) emerged in the United States in 2018 and has spread in both domestic and wild rabbits nationwide. The virus has a high mortality rate and can spread rapidly between infected individuals. Vaccination against RHDV2 provides the best protection against disease and should be considered by all rabbit owners. Here, we investigate the duration of immunity provided by vaccination with the Medgene Platform conditionally licensed commercial vaccine 6 months following the initial series. Rabbits received either the vaccination or a placebo and were challenged with RHDV2 6 months later. All vaccinated rabbits survived challenge whereas 18/19 non-vaccinated controls succumbed to infection within 10 or fewer days post-challenge. These results demonstrate lasting immunity following vaccination with the Medgene RHDV2 vaccine.

Keywords

rabbit hemorrhagic disease virus 2; RHDV2; vaccine; domestic rabbit

Subject

Biology and Life Sciences, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.